Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Clin Exp Immunol ; 164 Suppl 1: 11-3, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21447123

RESUMEN

Classification of vasculitis remains unsatisfactory. This is largely because the pathogenetic mechanisms of this family of related disorders have not been fully understood. Existing classification criteria are useful but limited. This has become more apparent with the advent of more effective and more specific therapies. A rational basis for classification could significantly improve our approach to treatment. The development of diagnostic criteria in vasculitis is an even greater challenge but may ultimately provide more useful for the non-specialist clinician. International efforts are underway to provide more effective classification and diagnostic criteria.


Asunto(s)
Vasculitis/clasificación , Humanos , Vasculitis/diagnóstico , Vasculitis/terapia
2.
Haemophilia ; 17(3): 463-9, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21118340

RESUMEN

Factor replacement with BIOSTATE(®), a factor VIII (FVIII)/von Willebrand factor concentrate, forms the mainstay of treatment for children with von Willebrand disorder (VWD) in Australia and New Zealand. However, published data on the clinical efficacy and safety of BIOSTATE in the VWD paediatric population are limited. We retrospectively assessed the efficacy and safety of BIOSTATE in 43 children with VWD who received treatment for surgery, non-surgical bleeds or continuous prophylaxis at eight paediatric haemophilia centres in Australia and New Zealand. Data were collected on patient demographics, disease history, treatment history, dosage, administration, adverse reactions, concomitant medications and excessive bleeding events. BIOSTATE provided excellent/good haemostatic efficacy in 90% of surgical procedures (n = 42) with a mean daily FVIII dose of 47 IU FVIII:C kg(-1) and a median treatment duration of 3 days. Excellent/good haemostatic efficacy was achieved in 94% of non-surgical bleeding events (n = 72) with a mean FVIII dose of 45 IU FVIII:C kg(-1) day(-1) and a median treatment duration of 1 day. There were no bleeding events attributable to lack of efficacy. One case of nausea, possibly related to BIOSTATE administration, was reported. These results suggest that BIOSTATE is safe and effective for the treatment and prophylaxis of bleeding in children with VWD.


Asunto(s)
Factor VIII/uso terapéutico , Hemorragia/prevención & control , Hemostáticos/uso terapéutico , Enfermedades de von Willebrand/tratamiento farmacológico , Factor de von Willebrand/uso terapéutico , Adolescente , Niño , Preescolar , Combinación de Medicamentos , Femenino , Hemostasis Quirúrgica/métodos , Humanos , Lactante , Masculino
5.
Leukemia ; 27(7): 1497-503, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23407458

RESUMEN

Children with acute lymphoblastic leukemia (ALL) and high minimal residual disease (MRD) levels after initial chemotherapy have a poor clinical outcome. In this prospective, single arm, Phase 2 trial, 111 Dutch and Australian children aged 1-18 years with newly diagnosed, t(9;22)-negative ALL, were identified among 1041 consecutively enrolled patients as high risk (HR) based on clinical features or high MRD. The HR cohort received the AIEOP-BFM (Associazione Italiana di Ematologia ed Oncologia Pediatrica (Italy)-Berlin-Frankfurt-Münster ALL Study Group) 2000 ALL Protocol I, then three novel HR chemotherapy blocks, followed by allogeneic transplant or chemotherapy. Of the 111 HR patients, 91 began HR treatment blocks, while 79 completed the protocol. There were 3 remission failures, 12 relapses, 7 toxic deaths in remission and 10 patients who changed protocol due to toxicity or clinician/parent preference. For the 111 HR patients, 5-year event-free survival (EFS) was 66.8% (±5.5) and overall survival (OS) was 75.6% (±4.3). The 30 patients treated as HR solely on the basis of high MRD levels had a 5-year EFS of 63% (±9.4%). All patients experienced grade 3 or 4 toxicities during HR block therapy. Although cure rates were improved compared with previous studies, high treatment toxicity suggested that novel agents are needed to achieve further improvement.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Trasplante de Células Madre Hematopoyéticas , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Asparaginasa/administración & dosificación , Asparaginasa/efectos adversos , Niño , Preescolar , Terapia Combinada , Ciclofosfamida/administración & dosificación , Ciclofosfamida/efectos adversos , Citarabina/administración & dosificación , Citarabina/efectos adversos , Daunorrubicina/administración & dosificación , Daunorrubicina/efectos adversos , Femenino , Humanos , Lactante , Estimación de Kaplan-Meier , Masculino , Mercaptopurina/administración & dosificación , Mercaptopurina/efectos adversos , Metotrexato/administración & dosificación , Metotrexato/efectos adversos , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidad , Prednisona/administración & dosificación , Prednisona/efectos adversos , Estudios Prospectivos , Inducción de Remisión , Factores de Riesgo , Trasplante Homólogo , Resultado del Tratamiento , Vincristina/administración & dosificación , Vincristina/efectos adversos
6.
Int J Lab Hematol ; 34(1): 98-101, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21707934

RESUMEN

A 2-year-old girl presented to casualty with a right knee effusion after apparently minor trauma. Inflicted injury was suspected and full forensic coagulation studies were performed which revealed a mild deficiency of factor VIII. Screening of the exons and intron/exon boundaries of F8 gene indicated that the child appeared to be homozygous for the missense mutation c.5123G>A (p.Arg1708His) in exon 14 of the F8 gene. This mutation has been reported to be associated with mild haemophilia A. The possibility of hemizygosity had been masked by the test kit employed but referral to the genetics service and subsequent array CGH resulted in a diagnosis of Turner syndrome.


Asunto(s)
Hemofilia A/diagnóstico , Síndrome de Turner/diagnóstico , Preescolar , Cromosomas Humanos X , Diagnóstico Diferencial , Exones , Factor VIII/genética , Femenino , Hemicigoto , Hemofilia A/complicaciones , Hemofilia A/genética , Homocigoto , Humanos , Traumatismos de la Rodilla/diagnóstico , Mutación , Síndrome de Turner/complicaciones , Síndrome de Turner/genética
10.
J Paediatr Child Health ; 29(2): 141-3, 1993 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-8387801

RESUMEN

Itraconazole is a new orally active antifungal agent shown to have in vitro and experimental activity against Aspergillus spp. This case report documents the successful eradication of biopsy-proven invasive pulmonary aspergillosis in a 17 year old boy with acute lymphocytic leukaemia. Cerebral involvement by the fungal infection was suspected clinically but was not biopsy proven. Although the patient subsequently died following bone marrow transplant and Escherichia coli septicaemia there was no evidence of residual Aspergillus at autopsy.


Asunto(s)
Antifúngicos/uso terapéutico , Aspergilosis/tratamiento farmacológico , Aspergillus fumigatus/efectos de los fármacos , Huésped Inmunocomprometido , Cetoconazol/análogos & derivados , Enfermedades Pulmonares Fúngicas/tratamiento farmacológico , Administración Oral , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Aspergilosis/inmunología , Humanos , Itraconazol , Cetoconazol/uso terapéutico , Enfermedades Pulmonares Fúngicas/inmunología , Masculino , Neutropenia/inducido químicamente , Neutropenia/inmunología , Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico
11.
Surg Endosc ; 12(2): 159-61, 1998 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-9479734

RESUMEN

The recent advent of laparoscopic splenectomy for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) has been embraced by surgeons and hematologists in many institutions. However, the occurrence of accessory splenic tissue in a proportion of such splenectomies, either concurrently or later, raises the question of how to deal with this problem when it arises. We report that the laparoscopic approach, facilitated by lateral positioning, can be successfully used for the treatment of an accessory spleen causing recurrent ITP. The use of intraoperative nuclear imaging can greatly aid the localization and provide confirmation of complete excision of the nuclear focus, especially for a very small accessory spleen.


Asunto(s)
Laparoscopía , Esplenectomía/métodos , Esplenosis/diagnóstico por imagen , Adulto , Femenino , Estudios de Seguimiento , Humanos , Periodo Intraoperatorio , Púrpura Trombocitopénica Idiopática/cirugía , Cintigrafía , Recurrencia , Reoperación , Esplenosis/cirugía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA